All Pharma News
Celgene Corp`s Reblozyl® (luspatercept-aamt) Receives Suppl Approval in US

Celgene Corp`s Reblozyl® (luspatercept-aamt) Receives Suppl Approval in US

FDA
16 May 2024
Share Share
Bristol Myers` bowel disease drug fails in late-stage study

Bristol Myers` bowel disease drug fails in late-stage study
REUTERS
29 Mar 2024
Share Share
Health Canada Issues Recall of Celgene Inc`s ISTODAX (romidepsin) – Restricted Access Program

Health Canada Issues Recall of Celgene Inc`s ISTODAX (romidepsin) – Restricted Access Program

HEALTH CANADA
20 Mar 2023
Share Share
Bristol Myers wins dismissal of a $6.4 billion lawsuit over cancer drug delay

Bristol Myers wins dismissal of a $6.4 billion lawsuit over cancer drug delay
REUTERS
02 Mar 2023
Share Share
Sun Pharma gets USFDA nod to market generic medication

Sun Pharma gets USFDA nod to market generic medication
ECONOMIC TIMES
10 Feb 2023
Share Share
Dr Reddy`s Lab among generic pharma companies in US to face antitrust litigation

Dr Reddy`s Lab among generic pharma companies in US to face antitrust litigation
ECONOMIC TIMES
23 Nov 2022
Share Share
BMS scores a topline treat in Reblozyl phase 3 study

BMS scores a topline treat in Reblozyl phase 3 study
Zoey Becker FIERCEPHARMA
01 Nov 2022
Share Share
Celgene, Acceleron alum Backstrom tapped to lead Scholar Rock

Celgene, Acceleron alum Backstrom tapped to lead Scholar Rock
Max Bayer FIERCEBIOTECH
20 Sep 2022
Share Share
Jounce’s latest setback dampens outlook for another cancer immunotherapy target

Jounce’s latest setback dampens outlook for another cancer immunotherapy target
Jonathan Gardner BIOPHARMADIVE
31 Aug 2022
Share Share
Celgene Corp`s Reblozyl® (luspatercept-aamt) Receives Approval in US

Celgene Corp`s Reblozyl® (luspatercept-aamt) Receives Approval in US
FDA
08 Jul 2022
Share Share